Title of article
Clinical pharmacology and the use of articaine for local and regional anaesthesia
Author/Authors
Tom B. Vree، نويسنده , , Mathieu J.M. Gielen، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2005
Pages
16
From page
293
To page
308
Abstract
Quicker onset and shorter elimination time favours (±) articaine as a short-acting local anaesthetic for regional anaesthesia in day-case settings, e.g. arthroscopy (shoulder, knee), hand and foot surgery, and dentistry, because patients treated with articaine will be ‘drug free’ more quickly than those who receive other local anaesthetics. Articaine diffuses better through soft tissue and bone than other local anaesthetics. The concentration of articaine in the alveolus of a tooth in the upper jaw after extraction was about 100 times higher than that in systemic circulation. Articaine is metabolised via hydrolysis into articainic acid, 75% of which in turn is excreted as such and 25% in the glucuronidated form by the kidneys.The half-lives of elimination (t½α and t½β) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours. Intrinsic half-lives of articainic acid are: t½α 12 minutes, and t½β 64 minutes (1 hour). In dentistry, articaine is the drug of choice in the vast majority of literature. In other regional anaesthesia techniques (intravenous regional anaesthesia, epidural, spinal and plexus blocks) there are not enough data to prove that (±) articaine is safer and more effective than the short-acting local anaesthetics lidocaine, (±) prilocaine or (±) mepivacaine.
Keywords
Pharmacokinetics , Articaine , Dentistry , articainic acid , articainic acid glucuronide , regional anaesthesia.
Journal title
Best Practice and Research Clinical Anaesthesiology
Serial Year
2005
Journal title
Best Practice and Research Clinical Anaesthesiology
Record number
465038
Link To Document